Recursion Pharmaceuticals, Inc.
RXRX
$3.16
-$0.15-4.53%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -60.10% | -56.11% | 681.74% | -80.16% | 33.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.10% | -56.11% | 681.74% | -80.16% | 33.34% |
| Cost of Revenue | -32.05% | -33.72% | -0.82% | 56.61% | 79.00% |
| Gross Profit | 27.89% | 31.31% | 29.93% | -115.48% | -88.58% |
| SG&A Expenses | -10.97% | -28.96% | -45.36% | 10.25% | 46.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.02% | -32.56% | -19.08% | 42.54% | 70.02% |
| Operating Income | 23.41% | 30.69% | 36.41% | -75.08% | -75.28% |
| Income Before Tax | 23.79% | 39.74% | 39.57% | -69.58% | -75.29% |
| Income Tax Expenses | -- | -2,813.92% | 185.71% | -98.20% | -- |
| Earnings from Continuing Operations | 23.79% | 41.97% | 39.56% | -69.29% | -76.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.79% | 41.97% | 39.56% | -69.29% | -76.23% |
| EBIT | 23.41% | 30.69% | 36.41% | -75.08% | -75.28% |
| EBITDA | 23.35% | 34.47% | 43.00% | -65.82% | -66.40% |
| EPS Basic | 40.28% | 55.84% | 61.44% | -7.02% | -2.28% |
| Normalized Basic EPS | 40.25% | 52.75% | 58.40% | -7.23% | -1.70% |
| EPS Diluted | 40.28% | 55.84% | 61.44% | -7.02% | -2.28% |
| Normalized Diluted EPS | 40.25% | 52.75% | 58.40% | -7.23% | -1.70% |
| Average Basic Shares Outstanding | 27.58% | 31.42% | 56.75% | 58.18% | 72.32% |
| Average Diluted Shares Outstanding | 27.58% | 31.42% | 56.75% | 58.18% | 72.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |